ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for HIV-1 Infection in Adults and Adolescents

Shots:

• The marketing authorization is based on GEMINI 1 & 2 studies result assessing Dovato vs dolutegravir + tenofovir disoproxil fumarate/emtricitabine in 1400+ patients with HIV-1 infection for 48wks.
• The GEMINI 1 & 2 studies result demonstrated that two drug regimen showed non-inferior efficacy based on plasma HIV-1 RNA <50 copies/ml compared three-drug regimen in treatment-naive HIV-1 infected patient
• Dovato (DTG 50 mg/3TC 300 mg) is an oral combination therapy and has received the US FDA’s approval in Apr’2019 for HIV-1 infection prior not treated with ARV with no resistance to DTG or 3TC

Click here to read full press release/ article | Ref: GSK | Image: PInterest